Iberdomide

Article details chemical synthesis, aromatic nitro reduction, yield analysis, cell culture, antibodies, fluorescence imaging, flow cytometry, cell extraction, IKZF1/3 degradation, immunoblot, cell viability, anti-bacterial assays, 4T1-Fluc-SD cell line generation, in vitro SD fused firefly luciferase degradation, animal studies, in vivo protein degradation, and reporting summary.

Immunomodulatory agents, monoclonal antibodies, bispecific antibodies, and CAR T-cell therapy have transformed multiple myeloma treatment. Despite improvements, MM remains incurable, prompting research into protein degradation and immune system activation. The triSpecific antibody JNJ-79635322 targets BCMA, GPRC5D, and CD3, showing promise in preclinical trials. Other approaches include BCMA-targeting ADCs like belantamab mafodotin and small molecule E3 ligase modulators like mezigdomide, aiming to enhance immunotherapies and prolong patient survival.

Belrestotug's revenue in the US is projected to reach $65 mn by 2039, according to GlobalData's Expiry Model. The rNPV model, which considers the risk of drug failure, is used for valuation. EOS-448, a checkpoint blocking antibody targeting TIGIT, is under development for various cancers. iTeos Therapeutics, with a FY2023 revenue of $12.6 mn, develops immuno-oncology drugs.